Human trial of Covaxin for children to begin soon

New Delhi, 18/5 (AO Bureau): Bharat Biotech and ICMR-produced Covid Vaccine Trial of Covaxin will be started within 10 to 12 days of children in the age group of 2 to 18, amid fears of threats from the third wave of corona virus. Dr. VK Paul, member of the NITI Aayog on health matters, gave information about this on Tuesday. Paul said that the Drug Controller General of India has approved the clinical trial of covaxin on children aged 2 to 18 years. As far as I am aware, in the next 10 to 12 days the trial of covaxin will start.

On the other hand, on the status of corona infection in the country, the central government said that cases of Covid-19 in Tamil Nadu, Tripura, Sikkim, Arunachal Pradesh, Manipur, Mizoram and increase in infection rate are being recorded, while Maharashtra, Uttar Pradesh, Delhi , Kovid-19 cases in Bihar, Madhya Pradesh and Chhattisgarh and there is a decline in infection rates. According to the data, about 1.8 percent of the total population of India has been affected by Kovid-19 so far, 98 percent of the population is still in a sensitive situation in terms of infection.

Covid cases are continuously decreasingThe Health Ministry said that the number of patients under Covid-19 under eight states is more than one lakh, the infection rate is more than 15 percent in 22 states. During the last 15 days, there has been a steady decrease in the number of patients under treatment of Covid-19, where it was 17.13 percent of the total cases of infection on May 3, while it has now come down to 13.3 percent.
The ministry said that the curve of the Covid-19 epidemic is stable in many states, due to overall efforts and increased investigation, it has stabilized. According to scientific analysis, reproduction numbers are now below 1 overall, which means that the scope of the Covid-19 epidemic is decreasing. There are 199 such districts where there has been a steady decline in the rate of infecting new cases and samples of Covid-19 for the last two weeks.

Comments are closed.